BMS, Enterome form microbiome pact | Chemical & Engineering News
Volume 94 Issue 46 | p. 15 | Concentrates
Issue Date: November 21, 2016

BMS, Enterome form microbiome pact

Department: Business
Keywords: oncology, Bristol-Myers Squibb, Enterome, microbiome

Bristol-Myers Squibb will pay Enterome $15 million up front as part of a pact to develop microbiome-derived biomarkers and therapeutics for cancer. The partners will also look for microbiome-derived biomarkers that could indicate whether a patient will benefit from BMS’s immuno-oncology treatments. Given growing evidence that the gut microbiome is involved in how the body responds or grows resistant to cancer immunotherapies, the companies hope to find new targets and therapies that could boost the efficacy of oncology drugs.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment